Clinical Trials Logo

Filter by:
NCT ID: NCT00102726 Completed - Thrombocytopaenia Clinical Trials

SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy

Start date: February 2005
Phase: Phase 2
Study type: Interventional

SB497115 is an oral agent which activates the thrombopoietin receptor and increases platelet counts in healthy volunteers. This study is examining several different doses of SB497115 versus placebo as treatment for patients with advanced solid tumors scheduled to receive chemotherapy with carboplatin and paclitaxel every 21 days. Patients will receive SB497115 on days 2-11 of each 21 day cycle for at least 2 cycles of chemotherapy and for a maximum of 8 cycles of chemotherapy.

NCT ID: NCT00099294 Completed - Pancreatic Cancer Clinical Trials

Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer

Start date: September 2004
Phase: Phase 3
Study type: Interventional

The primary objectives of the study is to evaluate the effectiveness and safety of glufosfamide in subjects with pancreatic cancer who have been previously treated with gemcitabine as measured by overall survival compared with best supportive care.

NCT ID: NCT00097955 Completed - Clinical trials for Diabetic Nephropathy

Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria

Start date: October 2004
Phase: Phase 2
Study type: Interventional

Study of the efficacy and safety of aliskiren when added to losartan and optimal antihypertensive therapy in patients with hypertension, type 2 diabetes, and kidney disorders to monitor improvement in any of these conditions.

NCT ID: NCT00097344 Terminated - Breast Neoplasms Clinical Trials

The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Start date: December 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether maximal estrogen suppression achieved via the combination of an experimental drug, atamestane, plus an FDA-approved drug, toremifene (Fareston®), is more effective than another approved drug, letrozole (Femara®), in delaying the growth of breast cancer, and whether the side effects of the combined hormonal therapy are different from the side effects of letrozole.

NCT ID: NCT00094549 Completed - Bipolar Disorder Clinical Trials

Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder

Start date: October 2004
Phase: Phase 4
Study type: Interventional

The goals of this study are: A. To determine whether olanzapine can help patients with bipolar disorder who currently have mild to moderate mania. B. To assess the safety of olanzapine and any side effects that might be associated with it, as well as the quality of life and functioning of patients treated with olanzapine. C. To assess how olanzapine compares to divalproex.

NCT ID: NCT00091442 Completed - Breast Cancer Clinical Trials

A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer

Start date: September 2004
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate whether the time to progression for the DOXIL and docetaxel combination therapy group was superior to that of the group treated with docetaxel monotherapy in participants with advanced breast cancer.

NCT ID: NCT00090051 Completed - Clinical trials for Chronic Lymphocytic Leukemia

FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients

Start date: July 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to provide treatment for patients who have chronic lymphocytic leukemia (CLL), and to compare the use of rituximab added to fludarabine+cyclophosphamide (FC) with FC alone, to determine if rituximab lengthens the time a patient remains free of leukemia symptoms.

NCT ID: NCT00090038 Completed - Clinical trials for Non-Hodgkin's Lymphoma

Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma

Start date: October 2003
Phase: Phase 4
Study type: Interventional

The purpose of this study is to provide treatment for patients who have relapsed Non-Hodgkin's lymphoma (NHL) or refractory NHL, and to test the immunity of study subjects after receiving four treatments with rituximab.

NCT ID: NCT00089986 Completed - Sepsis Clinical Trials

GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults

Start date: September 2004
Phase: Phase 2
Study type: Interventional

The primary objective is to estimate the size of the GR270773 treatment effect on 28-day all-cause mortality for two doses of GR270773 versus placebo in adult subjects with suspected or confirmed Gram-negative severe sepsis. GR270773 will be administered as a three-day continuous intravenous infusion.

NCT ID: NCT00089804 Terminated - Lupus Nephritis Clinical Trials

Study of LJP 394 in Lupus Patients With History of Renal Disease

ASPEN
Start date: October 2004
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to determine whether abetimus sodium is more effective than placebo in delaying time to renal flare in SLE patients with a history of renal disease.